Myeloproliferative　neoplasms　(MPNs)　are　blood　cell　disorders,　characterized　by　overproduction　of　abnormal　cells　in　bone　marrow　due　to　stem　cell　mutation.　The　proliferations　of　blood　cell　are　controlled　by　many　genes　particularly　MPL　gene　which　encodes　thrombopoietin　receptor,　a　hematopoietic　growth　factor　involved　in　the　production　and　regulation　of　the　platelets　and　multipotent　hematopoietic　progenitor　cells.　Acquired　mutations　including　(W515L　and　W515K)　in　this　gene　have　been　observed　in　patients　with　primary　myelofibrosis　or　essential　thrombocythemia　lacking　JAK2　(V617F)　mutations.　MPL　mutation　detection　is　important　for　MPNs　diagnosis,　but　due　to　low　frequency　of　mutant　allele　burden　(＜　15%)　may　be　missed　by　already　available　common　assays　such　as　Sanger　sequencing.　Furthermore,　these　techniques　are　costly,　time-consuming,　and　less　sensitive.　In　present　study,　we　aimed　to　develop　sensitive,　less　time-consuming,　and　cost-effective　real-time　PCR　assay　for　the　detection　of　MPL　mutations　that　is　based　on　TaqMan　fluorescent　probes.　DNA　was　extracted　from　blood　sample　of　128　MPNs　patients　collected　and　further　analysis　was　performed　on　TaqMan　RT-PCR.　Reference　curve　was　obtained　for　amplified　product　of　MPL　gene　containing　mutated　sequence.　The　predicted　sensitivity　level　was　at　least　5%　mutant　allele　burden　by　our　developed　assay　that　is　much　higher　than　sequencing　output.　Out　of　128,　2　(1.56%)　patients　harbored　W515L　mutation　and　1　(0.78%)　harbored　W515K　mutation.　It　was　concluded　that　TaqMan　qRT-PCR　assay　is　an　efficient,　sensitive,　cost-effective,　and　less　time-consuming　method　capable　of　detecting　MPL　mutation　in　MPNs　patients.　We　suggested　that　this　assay　might　be　helpful　in　investigating　mutant　allele　load　in　MPNs　patients.